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of the European Society for Immunodeficiencies and European
Group for Blood and Marrow Transplantation
Abstract
Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency with microthrombocytopenia,
eczema, recurrent infections, autoimmune disorders, and malignancies that are life-threatening in the
majority of patients. In this long-term, retrospective, multicenter study, we analyzed events that
occurred in 96 WAS patients who received transplants between 1979 and 2001 who survived at least 2
years following hematopoietic stem-cell transplantation (HSCT). Events included chronic
graft-versus-host disease (cGVHD), autoimmunity, infections, and sequelae of before or after HSCT
complications. Three patients (3%) died 2.1 to 21 years following HSCT. Overall 7-year event-free
survival rate was 75%. It was lower in recipients of mismatched related donors, also in relation with an
older age at HSCT and disease severity. The most striking finding was the observation of
cGVHD-independent autoimmunity in 20% of patients strongly associated with a mixed/split chimerism
status (P < .001), suggesting that residual-host lymphocytes can mediate autoimmune disease despite the
coexistence of donor lymphocytes. Infectious complications (6%) related to splenectomy were also
significant and may warrant a more restrictive approach to performing splenectomy in WAS patients.
Overall, this study provides the basis for a prospective, standardized, and more in-depth detailed
analysis of chimerism and events in long-term follow-up of WAS patients who receive transplants to
design better-adapted therapeutic strategies.
doi:10.1182/blood-2007-03-076679 
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TRANSPLANTATION
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Wiskott-Aldrich syndrome (WAS) is a rare
X-linked immunodeficiency with micro-
thrombocytopenia, eczema, recurrent in-
fections, autoimmune disorders, and ma-
lignancies that are life-threatening in the
majority of patients. In this long-term,
retrospective, multicenter study, we ana-
lyzed events that occurred in 96 WAS
patients who received transplants be-
tween 1979 and 2001 who survived at
least 2 years following hematopoietic
stem-cell transplantation (HSCT). Events
included chronic graft-versus-host dis-
ease (cGVHD), autoimmunity, infections,
and sequelae of before or after HSCT
complications. Three patients (3%) died
2.1 to 21 years following HSCT. Overall
7-year event-free survival rate was 75%. It
was lower in recipients of mismatched
related donors, also in relation with an
older age at HSCT and disease severity.
The most striking finding was the obser-
vation of cGVHD-independent autoimmu-
nity in 20% of patients strongly associ-
ated with a mixed/split chimerism status
(P < .001), suggesting that residual-host
lymphocytes can mediate autoimmune
disease despite the coexistence of donor
lymphocytes. Infectious complications
(6%) related to splenectomy were also
significant and may warrant a more re-
strictive approach to performing splenec-
tomy in WAS patients. Overall, this study
provides the basis for a prospective, stan-
dardized, and more in-depth detailed
analysis of chimerism and events in long-
term follow-up of WAS patients who re-
ceive transplants to design better-adapted
therapeutic strategies. (Blood. 2008;111:
439-445)
© 2008 by The American Society of Hematology
Introduction
Wiskott-Aldrich syndrome (WAS; OMIM 301000) is a rare X-
linked recessive disorder (incidence, 1-10:1 million) characterized
by bleeding secondary to micro-thrombocytopenia as well as
platelet dysfunction, defective lymphocyte function associated
with recurrent infections, eczema, autoimmune manifestations, and
later in life an increased incidence of lymphoma.1-6 The classic
WAS phenotype manifests itself as early as the neonatal period
with petechiae, bruises, bloody diarrhea, and infections such as
purulent otitis media, pneumonia, and eczema. In classic WAS,
mean platelet volume is 3.8 to 5.0 fL compared with 7.0 to 10.5 fL
in healthy subjects.4 In general, affected patients demonstrate both
cellular and humoral immunodeficiency leading to recurrent bacte-
rial, viral, and fungal infections. Immunologic abnormalities of
WAS include T-cell lymphopenia, defective proliferative response
to CD3 cross-linking, impaired antibody response to polysaccha-
ride antigens, defective monocyte chemotaxis, abnormalities of
stimulated dendritic cells, and an increased lymphocyte apoptosis
with age.7-12 Initially, most affected infants have normal number of
circulating lymphocytes, but lymphopenia usually develops by age
6 to 8 years or earlier, possibly due to increased apoptosis.9,11,12 The
gene responsible for WAS, the WAS protein gene (WASP), was
cloned and sequenced in 1994.5 The WASP gene has 12 exons and
Submitted March 6, 2007; accepted September 16, 2007. Prepublished online
as Blood First Edition paper, September 27, 2007; DOI 10.1182/blood-2007-
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encodes a 502 amino-acid protein (WASP), which is predominantly
expressed in nonerythroid hematopoietic cells.
WASP is a member of a family of proteins involved in
regulating actin polymerization. The dynamic nature of cytoskel-
etal changes plays a key role in a variety of cellular processes,
including lymphoid and myeloid development, platelet production,
efficient recruitment to the immune synapse formed between T- and
antigen-presenting cells, as well as cell adhesion and migration
through tissues and endothelial membranes, thus explaining the
complexity of the clinical phenotype.
Because of the complex structure and multifunctional design of
WASP and the variations in the clinical phenotype resulting from
mutations of the WASP gene, the correlation between phenotype
and genotype was examined by a number of investigators.5 Despite
the initially contradictory reports, in-depth analysis of large cohorts
of families with mutations leads to the conclusion that the clinical
phenotype is strongly influenced by the effect of the mutation on
the protein expression, correlating with a physician-graded scoring
system (score from 1 to 5) of the severity of WAS-associated
symptoms.13-18 The frequency and severity of infections, the extent
of eczema, and the progression to autoimmune diseases and
malignancies usually correlate with absence of WASP in patient
lymphocytes (scores 4 and 5). In contrast, scores of 1 to 3 describe
patients with milder forms of the disease.14-18 While this approach
can be useful in the clinical setting, caution is required because the
protein expression/phenotype correlation is not absolute and pa-
tients with residual full-length protein may still develop severe
manifestations.18,19 This relates presumably to the functionality of
the residual protein and in part to secondary genetic influences and
environmental factors. The prognosis of classic WAS with a
complete absence of WASP expression in the absence of hematopoi-
etic stem-cell transplantation (HSCT) is poor.3,19,20 Two major
high-risk groups have been identified: patients with autoimmune
manifestations and those with severe bleeding.19,20 HSCT is the
only curative approach to WAS providing correction of the
immunodeficiency and platelet disorder when appropriate myeloa-
blative and immunoablative conditioning regimen is used.20-29
Patients with matched sibling or parent donors (MSD) and
matched unrelated donors (URD) exhibit the highest survival rates
up to 80%, especially if transplantation occurs at an early age with
a URD.30-33 In the absence of a compatible donor, the use of a
mismatched related donor (MMRD) is associated with a signifi-
cantly lower survival rate.28,30,32-36 Taking into account the compli-
cated features of this disease, as well as the many different reasons
for HSCT, we have addressed the question of the long-term
outcome of these patients after transplantation in a multicenter
retrospective study, particularly looking at the long-term outcome
in patients surviving at least 2 years beyond HSCT, based on
before/per/after HSCT events, such as donor compatibility, disease
severity, and age at HSCT. The impact of splenectomy, relationship
between the degree of chimerism and autoimmune manifestations
following HSCT, immune reconstitution, as well as any other event
seriously affecting the long-term outcome were also considered.
Methods
The institutional review boards of each of the 19 participating centers
approved this study. For a list of the participating centers, see Document S1
(available on the Blood website; see the Supplemental Materials link at the
top of the online article). Informed consent was obtained in accordance with
the Declaration of Helsinki.
Ninety-six WAS patients who underwent HSCT and were alive with a
follow-up at least 2 years afterward were studied. The transplants were
performed in 19 centers from 14 European countries between 1979 and
2001. In the same period of time, 49 other patients with WAS received
transplants in these centers, but died within the first 2 years after HSCT.
European centers known to have performed HSCT for this condition were
identified from the Inborn Errors Working Party of the European Group for
Blood and Marrow Transplantation (EBMT) and from the European
Society for Immunodeficiency (ESID) database on WAS. The collaborating
centers completed a detailed questionnaire approved by the EBMT/ESID
group for each patient. Data collection was completed in December 2004.
Patient characteristics
Patient characteristics are shown in Table 1. The diagnosis was confirmed
by mutation analysis, family history, or by clinical and laboratory observa-
tions. Disease severity before transplantation was expressed as a score of
1 to 5 according to Ochs15 and Ochs and Thrasher.16 Splenectomy was
performed before HSCT in 28 of 96 patients (29%). Age at transplantation
ranged from 0.3 to 17.7 years (median, 2 years).
Procedures
Forty-five patients received an HSCT from an MSD. Of these, 42 were
siblings and 3 were parents. Hematopoietic stem cell (HSC) source was
bone marrow (BM) in 42 cases, or cord blood (CB) in 3 cases. Following
failure of an MMRD HSCT, one patient was retransplanted with marrow
from an MSD. Thirty-two patients received an HSCT from a URD. HSC
source was BM (n  24) or CD34 positively selected (n  8) peripheral
blood stem cells (PBSCs). Full compatibility data were available from
20 patients. Sixteen patients were 10/10 HLA antigen compatible, while
4 were HLA mismatched HLA at one locus. Nineteen patients received
22 HSCTs from an MMRD (BM n  15, PBSC n  5, BM  PBSC
n  2). All MMRDs were parents. Three patients had a second MMRD
HSCT within the year following the first HSCT. Eighty-five patients
received a conditioning regimen consisting of busulfan (16 or 20 mg/kg
total dose) and cyclophosphamide (200 mg/kg total dose) in accordance
with the EBMT guidelines.28,31-35 In vivo immunosuppression (anti–LFA-1
monoclonal antibodies with or without anti-CD2), alemtuzumab monoclo-
nal antibodies, or antithymocyte globulin was administered to 25 of
32 patients receiving a URD and 13 of 19 an MMRD HSCT, respectively.
Other regimens included fludarabine (150 mg/m2 total dose) and melphalan
(140 mg/m2 total dose). T-cell depletion was used in all of the MMRDs, in
5 of 32 URD, and in 2 of 45 MSD HSCTs. T-cell depletion methods
included E-rosetting, monoclonal antibodies or, since 1996, positive
selection of CD34 cells. Methotrexate was given as graft-versus-host
disease (GVHD) prophylaxis following HLA-identical HSCT and after
1983, cyclosporin A with or without a short course of methotrexate. Patients
who received a T cell–depleted transplant using either monoclonal antibod-
ies or E-rosetting received cyclosporin A. Recipients of CD34 HSC were
Table 1. Characteristics of Wiskott-Aldrich syndrome patients receiving transplants between 1979 and 2001 in 19 European centers and
surviving at least 2 years after HSCT
Donor group Median age, y (range) Median follow-up, y (range)
Disease severity score, no. patients
Splenectomy, no. patients2-3 4-5
MSD, n  45 2.3 (0.5-13.5) 8 (2-25) 25 20 7
URD, n  32 2.6 (0.33-17.7) 4.5 (2-14) 12 20 12
MMRD, n  19 1.8 (0.5-17) 11 (2-18) 4 15 9
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not given any further GVHD prophylaxis. GVHD was graded according to
standard criteria. Overall, 18 of 45 recipients of MSD (40%), 13 of
32 recipients of URD (40%), and 7 of 19 recipients of MMRD (37%)
HSCT, respectively, developed grade 2 or higher acute GVHD.
Assessment of HSCT outcome
Chimerism studies were performed by using several techniques, including
karyotyping, assessment of red blood cell antigens, immunoglobulin
allotypes, HLA-typing, Southern-blot hybridization, PCR analysis with
microsatellite probes, FISH, allele-specific antibodies to HLA, and WASP
protein staining. Full chimerism was defined by the presence of 95% or
more donor blood cells. Mixed donor chimerism was defined as a variable
percentage of donor cells ranging from 5% to 94% and split chimerism as
the presence of donor T cells associated with host myeloid and B cells.
Immunologic investigations
T and B lymphocyte counts and function were analyzed by standard
methods, ie, T- and B-cell enumeration using standard markers (CD3, CD4,
and CD8), in vitro T-cell proliferation tests, serum immunoglobulin
concentrations, and serum antibodies following immunization. T-cell
recovery was defined as CD3 cell count of more than 1 G/L with CD4 cell
count of more than 0.4 G/L, and positive mitogen and antigen-induced
proliferations. B-cell function was deemed to be satisfactory if a patient was
not receiving intravenous immunoglobulin. Ninety-six percent (43 of 45) in
the MSD group, and 84% (27 of 32) in the URD groups had T- and B-cell
recovery at 2 years after HSCT. In the MMRD group, 79% (15 of 19) had
T-cell and 74% (14 of 19) B-cell recovery at 2 years following HSCT.
Event-free survival
Time to any adverse event seriously affecting the outcome was measured
from 2 years after HSCT. For event-free survival (EFS), the following
adverse events were taken into account: autoimmunity, active chronic
GVHD (cGVHD), second HSCT, splenectomy after HSCT, death more than
2 years after HSCT, eczema lasting more than 2 years after transplant,
severe infectious complications, and both disease- and transplant-related
sequelae.
Statistics
Means were compared by the Student t test. Proportions were compared
using the 2 test for values of more than 5, Fisher exact test for those less
than or equal to 5. The tests were 2-sided. The EFS was calculated using the
product-limit method.37 Differences between the groups were assessed
using the log-rank test.38 Confidence intervals (CIs) were calculated from
standard errors (95% CI; 1.96  SE). Multivariate analysis was performed
using the Cox stepwise regression analysis to determine the independent
contribution of each prognostic factor.39 Data analysis was performed using
JMP version 6.0.3 statistical software (SAS Institute, Cary, NC).
Results
Survival, EFS, and chimerism
Of 96 patients who were alive at 2 years after HSCT, 93 are still
alive with a median follow-up of 7 years (range, 2-25 years). Three
late deaths were observed. One was due to fulminant meningococ-
cal sepsis at 25 months after transplantation in an otherwise healthy
but before HSCT splenectomized patient who was prescribed
penicillin prophylaxis. Another patient received a second haploiden-
tical transplantation 12 years after the first HSCT from the same
donor and died of Nocardia and Actinomyces sepsis at day 75 after
second HSCT. The third patient died from Addison disease at 21
years after HSCT because of poor compliance with treatment. The
overall 7-year EFS was 75%(95% CI, 66%-84%). The 7-year EFS
was significantly influenced by donor group: MSD HSCT 7-year
EFS 88% (95% CI, 78%-98%), URD HSCT 7-year EFS 71% (95%
CI, 55%-87%), and MMRD HSCT 7-year EFS 55% (95% CI,
33%-77%; Figure 1, P  .01). When each group is compared with
the other, the P values are the following: MSD versus MMRD,
P  .003; MSD versus URD, P  .03; URD versus MMRD,
P  .28. Of note, the power of the latter comparison was low due to
the more restricted number of patients in the MMRD group. The
impact of age and disease-severity factors (age, disease severity,
chimerism, autoimmunity, cGVHD, splenectomy) on the 7-year
EFS in all patients and as a function of HSCT donor origin is
presented in Tables 2 and 3. When considering all of the patients
(Table 2), chimerism, autoimmunity, cGVHD and splenectomy had
significant impact on 7-year EFS. However, when each group was
analyzed separately, age at transplantation, disease severity, and
splenectomy had a significant impact on EFS only in the MMRD
group (Table 3). A multivariate analysis of impact of various factors
on the 7-year EFS in all patients showed that chimerism and
cGVHD were the 2 independent variables significantly affecting
the EFS (Table 4). However, the nonsignificant impacts could be
linked to a lack of power given the restricted number of patients in
each group. Of the 96 patients analyzed, 78 had full chimerism and
Figure 1. Event-free survival in transplanted Wiskott-Aldrich syndrome pa-
tients according to donor group (P  .01). indicates the MSD group; …, URD
group; and  Y  Y, MMRD group.
Table 2. Influence of factors on 7-year event-free survival after
HSCT in all patients (univariate analyses)
Factor n 7-year EFS, % 95% CI P
Disease severity .12
2-3 41 87 77-97 —
4-5 55 64 50-78 —
Age .41
2 y or less 45 84 73-95 —
More than 2 y 51 68 55-81 —
cGVHD .003
No 89 80 72-88 —
Yes 7 21 0-56 —
Autoimmunity .005
No 77 83 75-91 —
Yes 19 45 20-70 —
Chimerism .004
Full 78 82 73-91 —
Mixed/split 18 46 23-69 —
Splenectomy .04
No 68 82 73-91 —
Yes 28 60 43-77 —
— indicates not applicable.
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18 had mixed or split chimerism at last report. No significant
difference was observed in the percentages of full-donor chimerism
among the 3 groups (Table 3).
GVHD
Seven patients (7%) had active cGVHD (MSD n 2, URD n 3,
MMRD n  2) at 2 years after HSCT. In the MSD group, one
patient had limited cGVHD that resolved in the third year after
HSCT, one patient had extensive cGVHD requiring immunosuppres-
sion until 7.5 years after HSCT. In the URD group, 2 patients had
extensive cGVHD lasting 3 and 5 years, respectively, after HSCT.
One patient had limited cGVHD resolving in the third year after
transplantation. Finally, in the MMRD group, one patient had
limited cGVHD, which resolved within 3 years after HSCT, and
one had extensive cGVHD requiring immunosuppression until
4 years after HSCT.
Autoimmune manifestations after HSCT
A striking observation is that 19 of 96 patients (20%) developed
autoimmune manifestations after HSCT independently of cGVHD
(Tables 5,6). Two other patients of the MSD group had autoimmu-
nity related to active cGVHD in the form of scleroderma and
vitiligo. None in the other groups had autoimmunity related to
cGVHD. Some patients had more than one manifestation. Autoim-
mune manifestations consisted of autoimmune thrombocytopenia
(n  10), autoimmune hemolytic anemia (n 3), neutropenia
(n  1), vasculitis (n 2), inflammatory bowel disease (n 1),
pericarditis (n 1), Addison disease (n 1), and autoimmune
hypothyroidy (n  4). Autoimmune manifestations appeared at a
median of 1.5 years after HSCT (4 months to 10 years). The median
duration of autoimmunity was 4 years (range, 1-20 years). Eight
(8%) patients had ongoing autoimmune manifestations at the time
of analysis. Autoimmune manifestations were more frequent in
recipients of URD (9 of 32; 28%) and MMRD (5 of 19; 26%) than
MSD HSCT (5 of 45; 11%; P  .04). We investigated whether
autoimmunity after HSCT correlated with occurrence of autoimmu-
nity before HSCT as a manifestation of WAS. Overall, 17 patients
had autoimmune manifestations before transplantation of which
7 persisted thereafter (P  .06). In the MSD group, 7 patients
had autoimmunity before HSCT of which only 1 persisted after
HSCT. In the URD group, of the 6 patients presenting autoimmu-
nity before transplantation, 3 (50%) had persistence of autoim-
mune manifestations. Finally, in the MMRD group, of the
4 patients with autoimmunity before transplantation, 3 (75%)
had persistence of autoimmunity. Conversely, autoimmunity
occurred de novo in 4 of 38 (11%) patients from the MSD,
in 6 of 26 (23%) patients from the URD, and in 2 of 15 (13%)
patients from the MMRD groups. The most striking observation
was the strong correlation between autoimmunity occurrence
and the chimerism pattern (Table 5). Overall, incidence of
autoimmunity was 6 of 78 (8%) in patients with full chimerism
and 13 of 18 (72%) in patients with mixed/split chimerism
(P  .001). Of note, 2 of 4 patients (MSD, n  2; URD, n 1;
MMRD, n 1) who had autoimmunity and had to be splenectomized at
7, 17, 19, and 20 months after HSCT developed severe infections (Table
Table 3. Influence of various factors on 7-year event-free survival
after hematopoietic stem cell transplantation (univariate analyses)
Factor n 7-year EFS, % 95% CI P *
MSD 45 88 78-98 —
Age —
2 y or less 22 95 86-100 .70
More than 2 y 23 81 64-98 —
Disease severity score —
2-3 24 91 80-100 .96
4-5 21 79 58-100 —
Splenectomy —
Yes 7 86 60-100 .87
No 38 88 77-99 —
URD 32 71 55-87 —
Age —
2 y or less 14 82 64-100 .10
More than 2 y 18 55 30-80 —
Disease severity score —
2-3 12 75 51-100 .84
4-5 20 70 50-90 —
Splenectomy —
Yes 12 69 48-90 .86
No 20 75 51-100 —
MMRD 19 55 33-77 —
Age —
2 y or less 9 75 51-100 .01
More than 2 y 10 25 0-55 —
Disease severity score —
2-3 4 100 .04
4-5 15 33 7-59 —
Splenectomy —
Yes 9 22 0-49 .04
No 10 82 59-100 —
— indicates not applicable.
*All P values are 2-sided and considered to be statistically significant for
P .05.
Table 4. Influence of various factors on event-free survival after
HSCT (multivariate analysis)
Factor HR 95% CI P
Age, 2 y or more vs 2 y or less 1.07 0.66-1.74 .80
Donor group, URD vs MSD 1.75 0.53-1.79 .17
Donor group, MMRD vs MSD 2.54 1.38-4.50 .17
Autoimmunity, yes vs no 1.05 0.62-1.83 .85
Splenectomy, yes vs no 1.12 0.66-1.96 .66
Disease severity score, more than 4-5 vs 2-3 1.16 0.70-1.92 .55
cGVHD, yes vs no 1.92 1.10-3.03 .02
Chimerism, mixed/split vs full 1.90 1.26-2.79 .003
HR indicates hazard ratio.
Table 5. Relationship between chimerism and autoimmunity after
HSCT
Patients, chimerism n
Autoimmunity
P *No Yes
All patients, n  96
Full 78 72 6 .001
Mixed/split 18 5 13 —
MSD, n  45
Full 41 37 4 .001
Mixed/split 4 3 1 —
URD, n  32
Full 23 21 2 .001
Mixed/split 9 2 7 —
MMRD, n  19
Full 14 14 0 .001
Mixed/split 5 0 5 —
— indicates not applicable.
*All P values are 2 sided and considered to be statistically significant for
P .05.
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7). A long-lasting T- and B-cell immunodeficiency was observed in
12 patients from all groups. In the MSD group, 4% (2 of 45) patients and
in the URD group 16% (5 of 32) patients had late T- and B-cell
recoveries at more than 2 years after HSCT. In the MMRD group, 21%
(4 of 19) patients had late T-cell recovery and 26% (5 of 19) had late
B-cell recovery. Late T- and B-cell recovery was found to be respec-
tively related to long-term immunosuppression for autoimmunity in
2 patients in the URD and 3 patients in the MMRD groups.
Other WAS-associated manifestations after HSCT
Two patients had developed non-Hodgkin lymphomas before
transplantation; they were in complete remission at the time of
HSCT. No malignancy occurred in the 96 patients following HSCT.
Only 2 patients had transient eczema and 1 patient asthma for 2,
2.9, and 3 years after HSCT, respectively. In all groups, none of the
nonsplenectomized patients developed severe infections after HSCT.
Table 7. WAS-associated sequelae
Donor group and age, y, at HSCT Score Splenectomy Type of sequelae
MSD*
0.8 5  Severe hearing deficiency
1.8 5  Severe hearing deficiency
1.3 4  Chronic sinusitis/mastoiditis; severe growth retardation
2.3 5  Bilateral equinus, spasticity, learning difficulties
7.0 5  Bronchiectasis, chronic restrictive pulmonary disease
2.5 5  Scleroderma, Sjögren’s syndrome
8.5 5  Extensive vitiligo
10.8 5  Bronchiectasis
URD†
3.0 5  Severe hearing deficiency
5.5 5  Anxiety, stereotype, school adaptation difficulties
8.3 5  Myocardial hypertrophy, retinopathy
17.7 5  Surgery for aortic root dilatation (vasculitis prior to HSCT)
7.6 4  Extensive chronic GVHD
2.8 5  Extensive chronic GVHD
MMRD‡
2.0 4  Severe neurologic sequelae following pneumococcal meningitis
1.8 4  Tendon retractions requiring surgery
2.4 4  Severe neurologic sequelae following pneumococcal meningitis
17.0 5  Kidney transplant from mother
4.5 5  Epilepsy, cognitive deficiency
5.0 5  Severe anorexia due to chronic digestive GVHD
 indicates yes; and, no.
*Of the 45 patients in this donor group, 8 had sequelae.
†Of the 32 patients in this donor group, 6 had sequelae.
‡Of the 19 patients in this donor group, 6 had sequelae.
Table 6. Autoimmune manifestations after HSCT
Donor group, no. patients Autoimmunity disease score before HSCT Chimerism Autoimmune manifestations after HSCT
MSD
1 5, AIHA, thrombocytopenia Full Thrombocytopenia*
2 3 Full Thrombocytopenia*
3 3 Full Autoimmune hypothyroidism
4 3 Split Thrombocytopenia, autoimmune hypothyroidism*
5 4 Full Addison disease
URD
1 5, AIHA Mixed Inflammatory bowel disease (6 mo after HSCT until 5 y)
2 3 Mixed Thrombocytopenia*
3 3 Split Autoimmune hypothyroidism
4 3 Full Thrombocytopenia*
5 3 Mixed Neutropenia, thrombocytopenia*
6 5, vasculitis Mixed Vasculitis
7 5, aortic vasculitis Full Pericarditis, AIHA
8 4 Mixed Autoimmune hypothyroidism
9 4 Mixed Thrombocytopenia*
MMRD
1 5, AIHA, thrombocytopenia Mixed AIHA
2 5, AIHA, thrombocytopenia Mixed Thrombocytopenia*
3 5, AIHA, thrombocytopenia Mixed AIHA, thrombocytopenia*
4 4 Mixed Vasculitis
5 4 Mixed Thrombocytopenia*
AIHA indicates autoimmune hemolytic anemia.
*Mean platelet volume: normal, detection of antiplatelet antibodies.
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In contrast, 6 of 28 (21%) splenectomized patients developed
severe infections after HSCT (P  .001). In the MSD group, 2 of
7 splenectomized patients (29%), in the URD group 1 of 12 (8%)
and in the MMRD group 3 of 9 (33%) had severe infections
including a fatal meningococcal sepsis.
Sequelae
Sequelae (Table 7) resulted either from irreversible tissue
damage that had taken place before HSCT or because of HSCT
complications such as cGVHD, autoimmunity, or severe infec-
tions in splenectomized patients. Sequelae were largely due to
damage before HSCT. Their frequency was highest in patients
who underwent an HSCT from a URD or MMRD donor,
possibly because a more risky HSCT was only undertaken in
patients with more severe WAS disease. Overall, 20 of 96 (20%)
patients had sequelae. There was a correlation between age at
HSCT and risk of sequelae since only 5 of 45 (11%) patients
transplanted at 2 years of age or younger had long-term sequelae
compared with 15 of 51 (29%) transplanted after 2 years of age
(P  .03). The risk of sequelae was highly significantly corre-
lated to the severity of disease before HSCT, since none of the
patients with score 2 or 3 developed sequelae, whereas 16 of
55 (29%) of patients with score 4 or 5 had sequelae (P  .002).
The 5 patients younger than 2 years at HSCT with sequelae were
all severely ill at time of transplant. They all underwent
splenectomy either before or after HSCT.
Discussion
In this long-term, multicenter, retrospective study on WAS
patients surviving 2 years or more following HSCT, we analyzed
the various events affecting quality of life. Our study is
comprehensive in that it includes a large cohort of WAS patients
treated with HSCT more than 22 years. The long time span is
also the weakness of the study because HSCT has improved dramati-
cally between 1979 and 2001 in terms of patient and donor selection, the
timing of HSCT, conditioning regimens, immunosuppression, and
infectious prophylaxis, among other factors. Another inevitable weak-
ness when gathering long-term data from such a rare disease is the
variations in experience between different centers. Despite these short-
comings, this retrospective study clearly confirms that for most patients
HSCT resolves and prevents the long-term, life-threatening complica-
tions associated with WAS, regardless of donor matching, although as
expected, long-term EFS is more likely to be better in recipients of MSD
HSCT or URD HSCT. Nevertheless, serious events such as autoimmu-
nity, infections, and sequelae can dramatically affect the quality of life
among some survivors.
The most striking finding not previously reported is the
occurrence of significant autoimmune manifestations indepen-
dently of cGVHD. Autoimmunity was significantly related to
mixed/split chimerism following HSCT, but not to pretransplant
autoimmunity. Autoimmune manifestations mostly targeted blood
cells and were antibody-mediated as is seen in WAS.17 Autoimmu-
nity led to prolonged immunosuppression and significant infectious
complications, particularly in patients who had splenectomy. The
strong association found between autoimmunity and mixed/split
chimerism as well as the WAS-like occurrence of autoimmune
manifestations after HSCT suggests that these complications were
mediated by residual-host lymphocytes. This finding could be
specific to WAS since autoimmunity after HSCT independent of
cGVHD is uncommon in other immune deficiencies.31 A more
detailed analysis of chimerism performed on different lymphocyte
lineages based primarily on WASP expression should provide
further insight into which host-cell lineages could provoke autoim-
munity. Because autoimmunity in WAS is complex, it will be of
particular importance to see whether the presence of host B cells is
sufficient to cause antibody-mediated autoimmunity and whether a
deficiency in donor regulatory T cells might account for emergence
of autoimmunity, as abnormal development/function of regulatory
T cells has been suggested to take place in WAS.40-42 The data from
this retrospective study suggest that quantification of the minimum
number/proportion of donor cells in each lymphocyte lineage
needed to prevent autoimmunity would be a useful aim for future
studies. Results of these studies will be critical to improve
strategies for HSCT in WAS patients as well as in developing
potential gene therapy trials.
Serious and even fatal infections following HSCT remain a
long-term risk in WAS patients, even 2 years after transplant.
According to our results, severe infections are clearly associated
with splenectomy, causing death in 2 patients and serious sequelae
in others. Therefore, in our view, splenectomy should not be
performed in patients with WAS who are candidates for HSCT or
who have already been treated with HSCT. Sequelae following
HSCT were strongly associated with very severe disease before
HSCT or with severe infection in splenectomized patients. In view
of these complications, it is important to transplant these patients
early. Patients younger than 2 years of age, including those
receiving a transplant from an MMRD, have a better chance of
long-term survival with a better quality of life than older patients at
HSCT. This work provides the basis for more detailed analysis of
consequences of chimerism on the precise outcome, and should be
used to define the indications and modalities for HSCT and
determine criteria for gene therapy.43 In the future, the latter would
likely need to achieve a high frequency of cell transduction
combined with adequate immunosuppression/myeloablation to
control autoimmunity. Autoimmune manifestations after HSCT
warrant further investigations in future prospective studies.
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